Treatment of immune thrombocytopenic purpura: focus on eltrombopag.
Immune thrombocytopenic purpura (ITP) is a relatively common autoimmune disorder in which antibodies are produced to circulating platelets. Symptoms can be mild, but for most patients the risk of severe bleeding is unacceptable and treatment is required. Glucocorticoids followed by splenectomy had been the mainstays of therapy. High dose intravenous immunoglobulin and anti-RhD therapy are available for patients with severe illness, but produce only temporary benefit. Rituximab may provide more durable responses, danazol may be underutilized, and immunosuppressants and cytotoxic agents are less often required. Recently the pathophysiology of ITP has been more clearly elucidated, particularly the importance of decreased production of platelets in most patients and the very blunted rise that occurs in serum thrombopoietin (TPO). The isolation of TPO and better understanding of its role in thrombopoiesis has led to the development of new highly effective treatments. TPO analogs had some successes in treating highly refractory ITP patients but were taken out of development due to TPO-antibody induction. Two second-generation TPO-mimetics, romiplostim and the orally available eltrombopag, have recently been licensed in some territories for the treatment of ITP. Approval of eltrombopag was based on results from Phase II and III placebo-controlled clinical trials and a long-term extension study. About 80% of patients achieve significant increases in platelet count (11% of placebo patients), with reduced bleeding and reduced use of concomitant medications; responses are often durable with no tachyphylaxis. The side effects of eltrombopag are generally mild and not worse than placebo, although there are concerns about hepatic dysfunction, and the potentials for thromboses, marrow reticulin fibrosis, rebound thrombocytopenia and cataracts. This is an important new option for highly refractory patients, and its niche in earlier treatment (and for other thrombocytopenic disorders) is yet to be defined.
Rice
Lawrence
L
Weill Cornell Medical College, Methodist Hospital, Houston, Texas, USA. lrice@tmhs.org
Lancet. 2009 Feb 21;373(9664):641-8
19231632
Blood. 2001 Dec 1;98(12):3241-8
11719360
N Engl J Med. 2007 Nov 29;357(22):2227-36
18046027
Blood. 2007 Jun 1;109(11):4739-41
17327409
N Engl J Med. 2006 Oct 19;355(16):1672-81
17050891
J Thromb Haemost. 2006 Nov;4(11):2377-83
16869934
Stem Cells. 2009 Feb;27(2):424-30
19038790
Am J Med. 1999 Apr;106(4):430-4
10225246
Prog Hematol. 1956;1:166-92
13359508
Curr Opin Investig Drugs. 2006 Sep;7(9):834-41
17002262
Blood. 2003 Aug 1;102(3):887-95
12676790
N Engl J Med. 1985 May 2;312(18):1170-4
4039036
J Clin Invest. 2005 Dec;115(12):3339-47
16322778
Blood. 1996 Jul 1;88(1):3-40
8704187
J Thromb Haemost. 2008 Apr;6(4):711-2; author reply 713
18221355
Blood. 1996 May 15;87(10):4068-71
8639762
Crit Rev Oncol Hematol. 2008 Jan;65(1):21-31
17681784
Am J Med. 2004 May 1;116(9):590-4
15093754
Am J Hematol. 2009 Jul;84(7):459-61
19484732
Eur J Haematol. 2008 Sep;81(3):165-9
18510702
Blood. 2002 Nov 15;100(10):3457-69
12411315
Am J Hematol. 2001 Nov;68(3):210-4
11754405
Blood. 2009 Mar 5;113(10):2161-71
18981291
Blood. 2004 Feb 15;103(4):1364-9
14576051
Br J Haematol. 2009 Feb;144(3):409-15
19016720
Blood. 2007 Feb 15;109(4):1401-7
17077333
Br J Haematol. 2007 Nov;139(3):351-62
17910625
Am J Hematol. 2008 Feb;83(2):93-6
17722078
Blood. 1992 May 1;79(9):2237-45
1571540
Stem Cells. 1998;16 Suppl 2:165-75
11012188
Pediatr Clin North Am. 2008 Apr;55(2):393-420, ix
18381093
Blood. 2004 Nov 1;104(9):2623-34
15217831
Ann Hematol. 2007 Oct;86(10):705-10
17503045
Lancet. 2008 Feb 2;371(9610):395-403
18242413
Am J Med. 2004 Dec 15;117(12):972-3; author reply 973
15629743
J Pediatr Hematol Oncol. 2003 Dec;25 Suppl 1:S57-61
14668642
Blood. 2000 Apr 15;95(8):2523-9
10753830
Blood. 2002 Jul 15;100(2):728-30
12091377
J Clin Invest. 1987 Jul;80(1):33-40
3597777
Blood. 1999 Mar 15;93(6):1951-8
10068668
Ann Intern Med. 2007 Jan 2;146(1):25-33
17200219
Am J Hematol. 1989 Apr;30(4):206-12
2929581
Semin Hematol. 2000 Jul;37(3):290-8
10942223
N Engl J Med. 2007 Nov 29;357(22):2237-47
18046028
Am J Hematol. 1982 Apr;12(2):167-77
7200322
Blood. 1998 Jun 15;91(12):4427-33
9616135